One-year dynamics of clinical activity during biologics therapy in patients of ulcerative colitis
Crohn’s & Colitis 360 · 08.07.2026 · 8 (3)
DOI: 10.1093/crocol/otag074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 03.07.2026. Verfasst von Yizhe Tie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangxi Key Research and Development Program, Guangxi Medical and Health Technology Development and Application Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Longitudinal trajectories and the optimal timing for evaluating clinical activity remains unclear in ulcerative colitis (UC) patients receiving biologics.
Methods
This study included 2705 UC patients from 5 trials and collected 28 807 records of partial Mayo scores (PMS) from baseline to week 52. Latent class growth mixed model was performed to construct 1-year PMS trajectories. Logistic regression assessed the association between PMS trajectories and 1-year therapeutic outcomes, and endoscopic remission was the primary outcome. Spearman correlation was utilized to identify the timepoints of PMS most correlated with the trajectories.
Results
Five trajectories of clinical activity were identified, including rapid remission (n = 590, 21.8%), delayed remission (n = 316, 11.7%), mild improvement (n = 748, 27.7%), slow improvement (n = 915, 33.8%), and relapse-fluctuation (n = 136, 5.0%) groups. Endoscopic and histological remission rates exhibited a progressive decline across trajectory groups, with the highest probability in the rapid remission group and sequentially lower probabilities in the delayed remission, mild/slow improvement, and relapse-fluctuation groups (P < .001). Week-20 PMS demonstrated the strongest correlation with clinical activity trajectories (correlation coefficient = 0.7867, P < .001), with an area under curve of 0.9311 (95% CI: 0.9183, 0.9440). Furthermore, week-20 PMS could independently predicted 1-year endoscopic (aOR [95% CI] 0.59 [0.54, 0.65], P < .001) and histological (aOR [95% CI] 0.61 [0.53-0.70], P < .001) remission.
Conclusions
UC patients receiving biologics would exhibit 5 distinct trajectories of clinical activity. Week 20 is a potential intermediate timepoint for clinical activity assessment to inform long-term outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- Guangxi Hospital Division, The First Affiliated Hospital, Sun Yat-sen University, Nanning, China.
ORCID-Profile: Yizhe Tie, Minhu Chen, Shenghong Zhang
Förderung
- Guangxi Key Research and Development Program
- Guangxi Medical and Health Technology Development and Application Project
- National Natural Science Foundation of China
- Guangdong Province Medical Science and Technology Research Fund
- China Crohn’s & Colitis Foundation
Zitieren
APA
Tie, Y., Su, F., Zhang, J., Zheng, M., Li, N., Zheng, J., Chen, M., Chen, R., Li, L., & Zhang, S. (2026). One-year dynamics of clinical activity during biologics therapy in patients of ulcerative colitis. Crohn’s & Colitis 360, 8(3). https://doi.org/10.1093/crocol/otag074
Vancouver
Tie Y, Su F, Zhang J, Zheng M, Li N, Zheng J, et al. One-year dynamics of clinical activity during biologics therapy in patients of ulcerative colitis. Crohn’s & Colitis 360. 2026;8(3). doi:10.1093/crocol/otag074
BibTeX
@article{Tie2026,
author = {Tie, Yizhe and Su, Fengyuan and Zhang, Jianwu and Zheng, Minhui and Li, Ningyi and Zheng, Jieqi and Chen, Minhu and Chen, Rirong and Li, Li and Zhang, Shenghong},
title = {One-year dynamics of clinical activity during biologics therapy in patients of ulcerative colitis},
journal = {Crohn’s & Colitis 360},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/crocol/otag074}
}
EUVIMED